A new study presented at IDWeek 2024 reveals that race and socioeconomic vulnerabilities significantly impact vaccine uptake ...

New IDWeek 2024 study reveals disparities in PrEP uptake across key U.S. populations. While overall PrEP usage has increased, ...

ATI-1701 provides full protection against lethal tularemia in animal models after one yearCompany to provide update on tularemia vaccine ...

Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced the upcoming presentations of pemivibart data from ...

SAN DIEGO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® ...

OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President & CEO: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announces new data ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Ferring Pharmaceuticals today announced the presentation of two data analyses at IDWeek 2024 evaluating the efficacy and safety of REBYOTA ® (fecal microbiota, live – jslm) administered in a ...

CA from October 16-19, 2024. Data to be presented at IDWeek 2024 include: ...

today announced the upcoming presentations of pemivibart data from its Phase 1 and Phase 3 clinical trials at IDWeek 2024. The conference is being held in Los Angeles, October 16-19, 2024.